Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
KING OF PRUSSIA, Pa., July 20 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the initiation of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the dose escalation and...
Is Obesity an Oral Bacterial Disease?
ALEXANDRIA, Va., July 9 /PRNewswire-USNewswire/ -- The world-wide explosion of overweight people has been called an epidemic. The inflammatory nature of obesity is widely recognized. Could it really be an epidemic involving an infectious agent? In this climate of concern over the increasing preval...
School of Dentistry Studies Link Between Oral Health and Memory
MORGANTOWN, W.Va., June 19 /PRNewswire-USNewswire/ -- Keeping your teeth brushed and flossed can cut down on gum disease, drastically reducing risk of heart attack and stroke, dentists have warned for years. Now researchers at West Virginia University have found a clean mouth may also help prese...
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented today at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sug...
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference Oral
CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability Profile
MOUNTAIN VIEW, Calif., June 1 /PRNewswire/ -- ChemoCentryx, Inc., announced that Phase II/III clinical data from the company's PROTECT-1 (the P rospective R andomized O ral T herapy E valuation in ...
Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.
(OTC: ORMP) ( http://www.oramed.com ), a developer of oral
announced that Phase 2b clinical trials will commence this week on 30 Type 2
Diabetic volunteers. The study is intended to evaluate the safety,
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be...
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources
WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceut...
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC ) today announced that it has begun treating patients in a Phase
1 dose-escalation study to evaluate the safety and tolerability of PCI-32765,
an orally available, selective inhibitor of Bruton's tyrosine ...
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
NEW YORK, March 31 /PRNewswire/ -- Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral
delivery, a new study suggests. The study was conducted by res...
Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals,
Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral
systems, announced today that it has been selected to present the results
from the study, entitled, "Open Label Study to Assess the Safety,
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy
KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...
American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
NEW YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental
Bioengineering, Inc. (NYSE: AOB ), a China-based pharmaceutical company
dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter ("OTC")
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Highly Statistically Significant Results Achieved at Two Dose Levels with No Reversal of Analgesia
SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled ...
Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection
PHILADELPHIA, Feb. 12 /PRNewswire-USNewswire/ -- When treating children for acute osteomyelitis--a bacterial bone infection--an early changeover from intravenous (IV) antibiotic delivery to oral
antibiotics is just as effective as continuing the IV therapy, according to pediatric researchers.
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral
Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA).
The primary objectives of this safety and tolerability study have been achieved. T...
Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis
SAN DIEGO, Jan. 22 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a dose-ranging Phase 2b clinical trial to evaluate oral
viscous budesonide (OVB) for the treatment of children and adolescents with eosinophilic esophagitis (EoE), an allergic inflammatory condition of t...
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care-
NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral
Xeloda(R) plus oxaliplatin (XELOX) is comp...
Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally a...
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs that
provide significant advances in cardiovascular disease, inflammatory disease
and cancer, today announced that it has initiated patient enrollment in
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular
atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of
DU-176b, an investigational oral
Factor Xa inhibitor, experienced comparable
safety and tolerability compared to those taking warfarin, according to new...
TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral
presentation of preliminary results from a multi-center, US-based clinical
trial of TG101348 in myeloproliferative disease patients has been scheduled at
the 2008 American Society of Hematology (ASH) Meeting.
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Company reaffirms its innovation leadership and long-term commitment to hepatitis research
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral
hepatitis C protease inhi...
FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
PHILADELPHIA, Nov. 20 /PRNewswire-FirstCall/ --GlaxoSmithKline (NYSE: GSK ) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immu...
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc.
(Nasdaq: VRUS ), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN ) today
announced that the first patients have been dosed in an innovative clinical
trial in patients chronically infected with the hepatitis C virus (HCV)....
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused
on oncology, today announced top-line results from its Phase 1 clinical
trial of an oral
formulation of picoplatin in patients with solid tumors
Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
Data to be presented at annual ICAAC/IDSA meeting in Washington, D.C.
WASHINGTON, Oct. 28 /PRNewswire/ -- Scientists at NanoBio Corporation
have demonstrated for the first time in humans that a novel topical
treatment for cold sores (herpes labialis), NB-001, speeds healing of
lesions as effe...
Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Study to Assess the Safety and Efficacy of ORMD 0801, Oral
Insulin Capsule, on Type 1 Diabetics
JERUSALEM, Israel, September 24 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
delivery systems, announ...
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida
Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase
II 'intravenous-to-oral' switch trial with oral
iclaprim in patients with
complicated Skin and Skin Structure Infections (cSSSI).
The trial was design...
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the
initiation of multi-center Phase I clinical trials of SB1518, a potent and
orally-active JAK2 inhibitor, in patients with leukemia and certain types
of lymphoma. These first Phase I trials for SB1518 comprise of ascending
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class
WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a
leader in the development of small molecule anti-infective drugs, announced
today the initiation of a Phase ...
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today
at the Annual Congress of the European Society of Cardiology showed that
the investigational oral
Factor Xa inhibitor DU-176b reduced the incidence
of venous thromboembolism (VTE) compared with dalteparin among patients
Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
JERUSALEM, Israel, August 18 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
delivery systems, announced today that its abstract, entitled "Open
Label Study to Assess the Safety, Pharmacokinetics (PK) and
Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
The Trial Demonstrated the Safety and Efficacy of the ORMD 0801- Oral
JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP)( http://www.oramed.com ), a developer of
oral delivery systems, announced today suc...
Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
Phase III Study to Explore the Effects of Eligen(R) Delivery Technology and Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women
CEDAR KNOLLS, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG
has finished ...
Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
JERUSALEM, July 31 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals,
Inc. (OTCBB: ORMP) ( http://www.oramed.com ), a developer of oral
systems, announced today that it will hold a conference call on August 6,
2008 at 10:30 AM EDT to present the results of its Phase 2A clinical trials
Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
GLP-1 Has Potential to Treat Type 2 Diabetes Using Emisphere's Eligen(R) Technology
CEDAR KNOLLS, N.J., July 8 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a clinical
study assessing the oral
delivery of GLP...
Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
HOUSTON, July 1 /PRNewswire/ -- Agennix Incorporated today announced
the publication of final results from a Phase 2 monotherapy trial with
talactoferrin alfa in patients who had failed previous treatment for
advanced or metastatic renal cell carcinoma (RCC). Results from the study,
Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on Healthy Postmenopausal Women
CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG
has launched a Phase I study in...
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
Clinical Studies Expected to Restart in Second Half 2008
BERKELEY HEIGHTS, N.J., June 23 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced that the Company has
received notification from the U.S. Food and Drug Administration (FDA) that
Genta may resume c...